Search

Your search keyword '"Kitchener, Henry"' showing total 395 results
Start Over Author "Kitchener, Henry" Language english
395 results on '"Kitchener, Henry"'

2. Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy

Author

Wortman, Bastiaan G., Post, Cathalijne C.B., Powell, Melanie E., Khaw, Pearly, Fyles, Anthony, D'Amico, Romerai, Haie-Meder, Christine, Jürgenliemk-Schulz, Ina M., McCormack, Mary, Do, Viet, Katsaros, Dionyssios, Bessette, Paul, Baron, Marie Hélène, Nout, Remi A., Whitmarsh, Karen, Mileshkin, Linda, Lutgens, Ludy C.H.W., Kitchener, Henry C., Brooks, Susan, Nijman, Hans W., Astreinidou, Eleftheria, Putter, Hein, Creutzberg, Carien L., and de Boer, Stephanie M.

Published
2022
Full Text
View/download PDF

3. Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial

Author

Post, Cathalijne C.B., de Boer, Stephanie M., Powell, Melanie E., Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Nelleke (P.) B., Ledermann, Jonathan A., Khaw, Pearly, D'Amico, Romerai, Fyles, Anthony, Baron, Marie Hélène, Kitchener, Henry C., Nijman, Hans W., Lutgens, Ludy C.H.W., Brooks, Susan, Jürgenliemk-Schulz, Ina M., Feeney, Amanda, Goss, Geraldine, Fossati, Roldano, Ghatage, Prafull, Leary, Alexandra, Do, Viet, Lissoni, Andrea A., McCormack, Mary, Nout, Remi A., Verhoeven-Adema, Karen W., Smit, Vincent T.H.B.M., Putter, Hein, and Creutzberg, Carien L.

Published
2021
Full Text
View/download PDF

4. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

Author

McCormack, M, Whitmarsh, K, Allerton, R, Gregory, D, Symonds, P, Hoskin, PJ, Adusumalli, M, Anand, A, Wade, R, Stewart, A, Taylor, W, Lutgens, LCHW, Hollema, H, Pras, E, Snyers, A, Westerveld, GH, Jobsen, JJ, Slot, A, Mens, JM, Stam, TC, Van Triest, B, Van der Steen-Banasik, EM, De Winter, KAJ, Quinn, MA, Kolodziej, I, Pyman, J, Johnson, C, Capp, A, Fossati, R, Colombo, A, Carinelli, S, Ferrero, A, Artioli, G, Davidson, C, McLachlin, CM, Ghatage, P, Rittenberg, PVC, Souhami, L, Thomas, G, Duvillard, P, Berton-Rigaud, D, Tubiana-Mathieu, N, de Boer, Stephanie M, Powell, Melanie E, Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Petronella B, Ledermann, Jonathan A, Khaw, Pearly, D'Amico, Romerai, Fyles, Anthony, Baron, Marie-Helene, Jürgenliemk-Schulz, Ina M, Kitchener, Henry C, Nijman, Hans W, Wilson, Godfrey, Brooks, Susan, Gribaudo, Sergio, Provencher, Diane, Hanzen, Chantal, Kruitwagen, Roy F, Smit, Vincent T H B M, Singh, Naveena, Do, Viet, Lissoni, Andrea, Nout, Remi A, Feeney, Amanda, Verhoeven-Adema, Karen W, Putter, Hein, and Creutzberg, Carien L

Published
2019
Full Text
View/download PDF

5. Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative

Author

Auguste, Aurélie, Genestie, Catherine, De Bruyn, Marco, Adam, Julien, Le Formal, Audrey, Drusch, Françoise, Pautier, Patricia, Crosbie, Emma J., MacKay, Helen, Kitchener, Henry C., Powell, Melanie, Pollock, Pamela M., Mileshkin, Linda, Edmondson, Richard J., Nout, Remi, Nijman, Hans W., Creutzberg, Carien L., Bosse, Tjalling, and Leary, Alexandra

Published
2018
Full Text
View/download PDF

6. 3408: Ten-year results of the PORTEC-3 trial: adjuvant therapy for women with high-risk endometrial cancer

Author

Post, Cathalijne C B, de Boer, Stephanie M., Powell, Melanie E., Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Leary, Alexandra, Ottevanger, Nelleke P., McCormack, Mary, Khaw, Pearly, D’Amico, Romerai, Fyles, Anthony, Chargari, Cyrus, Kitchener, Henry C., Nijman, Hans W., Lutgens, Ludy, Jürgenliemk-Schulz, Ina M., Nout, Remi A., Putter, Hein, Horeweg, Nanda, Bosse, Tjalling, and Creutzberg, Carien L.

Published
2024
Full Text
View/download PDF

10. Working together to shape the endometrial cancer research agenda: The top ten unanswered research questions

Author

Wan, Y. Louise, Beverley-Stevenson, Rachel, Carlisle, Daloni, Clarke, Sinead, Edmondson, Richard J., Glover, Steve, Holland, Julie, Hughes, Carol, Kitchener, Henry C., Kitson, Sarah, Miles, Tracie, Morley, Richard, Morrison, Jo, Nelson, Linsey, Powell, Melanie, Sadler, Laura, Tomlinson, Anne, Tylko-Hill, Katharine, Whitcombe, Jo, and Crosbie, Emma J.

Published
2016
Full Text
View/download PDF

11. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

Author

Wheeler, Cosette M, Skinner, S Rachel, Del Rosario-Raymundo, M Rowena, Garland, Suzanne M, Chatterjee, Archana, Lazcano-Ponce, Eduardo, Salmerón, Jorge, McNeil, Shelly, Stapleton, Jack T, Bouchard, Céline, Martens, Mark G, Money, Deborah M, Quek, Swee Chong, Romanowski, Barbara, Vallejos, Carlos S, ter Harmsel, Bram, Prilepskaya, Vera, Fong, Kah Leng, Kitchener, Henry, Minkina, Galina, Lim, Yong Kuei Timothy, Stoney, Tanya, Chakhtoura, Nahida, Cruickshank, Margaret E, Savicheva, Alevtina, da Silva, Daniel Pereira, Ferguson, Murdo, Molijn, Anco C, Quint, Wim G V, Hardt, Karin, Descamps, Dominique, Suryakiran, Pemmaraju V, Karkada, Naveen, Geeraerts, Brecht, Dubin, Gary, and Struyf, Frank

Published
2016
Full Text
View/download PDF

12. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial

Author

de Boer, Stephanie M, Powell, Melanie E, Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Petronella B, Ledermann, Jonathan A, Khaw, Pearly, Colombo, Alessandro, Fyles, Anthony, Baron, Marie-Helene, Kitchener, Henry C, Nijman, Hans W, Kruitwagen, Roy F, Nout, Remi A, Verhoeven-Adema, Karen W, Smit, Vincent T, Putter, Hein, and Creutzberg, Carien L

Published
2016
Full Text
View/download PDF

13. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial

Author

Kehoe, Sean, Hook, Jane, Nankivell, Matthew, Jayson, Gordon C, Kitchener, Henry, Lopes, Tito, Luesley, David, Perren, Timothy, Bannoo, Selina, Mascarenhas, Monica, Dobbs, Stephen, Essapen, Sharadah, Twigg, Jeremy, Herod, Jonathan, McCluggage, Glenn, Parmar, Mahesh, and Swart, Ann-Marie

Published
2015
Full Text
View/download PDF

15. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

Author

Skinner, S Rachel, Szarewski, Anne, Romanowski, Barbara, Garland, Suzanne M, Lazcano-Ponce, Eduardo, Salmerón, Jorge, Del Rosario-Raymundo, M Rowena, Verheijen, René H M, Quek, Swee Chong, da Silva, Daniel P, Kitchener, Henry, Fong, Kah Leng, Bouchard, Céline, Money, Deborah M, Ilancheran, Arunachalam, Cruickshank, Margaret E, Levin, Myron J, Chatterjee, Archana, Stapleton, Jack T, Martens, Mark, Quint, Wim, David, Marie-Pierre, Meric, Dorothée, Hardt, Karin, Descamps, Dominique, Geeraerts, Brecht, Struyf, Frank, and Dubin, Gary

Published
2014
Full Text
View/download PDF

19. Risk of Newly Detected Infections and Cervical Abnormalities in Women Seropositive for Naturally Acquired Human Papillomavirus Type 16/18 Antibodies: Analysis of the Control Arm of PATRICIA

Author

Castellsagué, Xavier, Naud, Paulo, Chow, Song-Nan, Wheeler, Cosette M., Germar, Maria Julieta V., Lehtinen, Matti, Paavonen, Jorma, Jaisamrarn, Unnop, Garland, Suzanne M., Salmerón, Jorge, Apter, Dan, Kitchener, Henry, Teixeira, Julio C., Skinner, S. Rachel, Limson, Genara, Szarewski, Anne, Romanowski, Barbara, Aoki, Fred Y., Schwarz, Tino F., Poppe, Willy A. J., Bosch, F. Xavier, de Carvalho, Newton S., Peters, Klaus, Tjalma, Wiebren A. A., Safaeian, Mahboobeh, Raillard, Alice, Descamps, Dominique, Struyf, Frank, Dubin, Gary, Rosillon, Dominique, and Baril, Laurence

Published
2014

20. Cervical Cancer: A Global Health Crisis

Author

Small, William, Jr, Bacon, Monica A., Bajaj, Amishi, Chuang, Linus T., Fisher, Brandon J., Harkenrider, Matthew M., Jhingran, Anuja, Kitchener, Henry C., Mileshkin, Linda R., Viswanathan, Akila N., and Gaffney, David K.

Published
2017
Full Text
View/download PDF

24. Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial

Author

Roset Bahmanyar, Edith, Paavonen, Jorma, Naud, Paulo, Salmerón, Jorge, Chow, Song-Nan, Apter, Dan, Kitchener, Henry, Castellsagué, Xavier, Teixeira, Julio C., Skinner, S. Rachel, Jaisamrarn, Unnop, Limson, Genara A., Garland, Suzanne M., Szarewski, Anne, Romanowski, Barbara, Aoki, Fred, Schwarz, Tino F., Poppe, Willy A.J., De Carvalho, Newton S., Harper, Diane M., Bosch, F. Xavier, Raillard, Alice, Descamps, Dominique, Struyf, Frank, Lehtinen, Matti, and Dubin, Gary

Published
2012
Full Text
View/download PDF

26. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

Author

Wheeler, Cosette M, Castellsagué, Xavier, Garland, Suzanne M, Szarewski, Anne, Paavonen, Jorma, Naud, Paulo, Salmerón, Jorge, Chow, Song-Nan, Apter, Dan, Kitchener, Henry, Teixeira, Júlio C, Skinner, S Rachel, Jaisamrarn, Unnop, Limson, Genara, Romanowski, Barbara, Aoki, Fred Y, Schwarz, Tino F, Poppe, Willy A J, Bosch, F Xavier, Harper, Diane M, Huh, Warner, Hardt, Karin, Zahaf, Toufik, Descamps, Dominique, Struyf, Frank, Dubin, Gary, and Lehtinen, Matti

Published
2012
Full Text
View/download PDF

27. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

Author

Lehtinen, Matti, Paavonen, Jorma, Wheeler, Cosette M, Jaisamrarn, Unnop, Garland, Suzanne M, Castellsagué, Xavier, Skinner, S Rachel, Apter, Dan, Naud, Paulo, Salmerón, Jorge, Chow, Song-Nan, Kitchener, Henry, Teixeira, Júlio C, Hedrick, James, Limson, Genara, Szarewski, Anne, Romanowski, Barbara, Aoki, Fred Y, Schwarz, Tino F, Poppe, Willy A J, De Carvalho, Newton S, Germar, Maria Julieta V, Peters, Klaus, Mindel, Adrian, De Sutter, Philippe, Bosch, F Xavier, David, Marie-Pierre, Descamps, Dominique, Struyf, Frank, and Dubin, Gary

Published
2012
Full Text
View/download PDF

33. Mortality Associated with Oral Contraceptive Use

Author

Szarewski, Anne, Kitchener, Henry C., Horowitz, Joseph, Kahlenborn, Chris, Grant, Ellen C. G., Steel, C. Michael, Price, Elizabeth H., Anthony, Honor M., Downing, Damien, Radcliffe, Michael J., and Myhill, Sarah

Published
1999

37. Cytology interpretation after a change to HPV testing in primary cervical screening: Observational study from the English pilot.

Author

Rebolj, Matejka, Mathews, Christopher S., Denton, Karin, Appleyard, Tracey‐Louise, Cruickshank, Margaret, Cuschieri, Kate, Ellis, Kay, Evans, Chris, Frew, Viki, Giles, Thomas, Gray, Alastair, Holbrook, Miles, Hunt, Katherine, Kitchener, Henry, Levine, Tanya, McBride, Emily, Mesher, David, Palmer, Timothy, Parker, Janet, and Rimmer, Elizabeth

Abstract

BACKGROUND: Overcalling of abnormalities has been a concern for using cytology triage after positive high‐risk human papillomavirus (HPV) tests in cervical screening. METHODS: The authors studied the detection of cytological and histological abnormalities at age 24 to 64 years, using data from the English HPV pilot. The pilot compared routine implementation of primary cervical screening based on cytology (N = 931,539), where HPV test results were not available before cytology reporting, with that based on HPV testing (N = 403,269), where cytology was only required after positive HPV tests. RESULTS: Revealed HPV positivity was associated with a higher direct referral to colposcopy after any abnormality (adjusted odds ratio [ORadj], 1.16; 95% confidence interval [CI], 1.14‐1.18). Laboratories with higher direct referral referred fewer persistently HPV‐positive women after early recall. The detection of high‐grade cervical intraepithelial neoplasia (CIN2+) after direct referral increased with an ORadj of 1.17 (95% CI, 1.13‐1.20) for informed versus uninformed cytology. Generally, the positive predictive value (PPV) of colposcopy for CIN2+ remained comparable under both conditions of interpreting cytology. In women 50 to 64 years old with high‐grade dyskaryosis, however, the PPV increased from 71% to 83% after revealing HPV positivity (ORadj, 2.05; 95% CI, 1.43‐2.93). CONCLUSIONS: Quality‐controlled cervical screening programs can avoid inappropriate overgrading of HPV‐positive cytology.; These population‐based data show that the interpretation of triage cytology informed by a positive human papillomavirus (HPV) test can contribute to a higher overall detection of high‐grade cervical intraepithelial neoplasia without a concomitant increase in overreferral of low‐risk women. The practices used in England, where the national cervical screening program is quality‐assured using rigorous national standards, may serve as a model for screening settings where revealing HPV positivity has led to overgrading of cytology. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

38. Age‐specific outcomes from the first round of HPV screening in unvaccinated women: Observational study from the English cervical screening pilot.

Author

Rebolj, Matejka, Mathews, Christopher S., Pesola, Francesca, Cuschieri, Kate, Denton, Karin, Kitchener, Henry, Appleyard, Tracey‐Louise, Cruickshank, Margaret, Ellis, Kay, Evans, Chris, Frew, Viki, Giles, Thomas, Gray, Alastair, Holbrook, Miles, Hunt, Katherine, Levine, Tanya, McBride, Emily, Mesher, David, Palmer, Timothy, and Parker, Janet

Subjects
MEDICAL screening, CERVICAL intraepithelial neoplasia, VACCINATION status, VACCINATION, SCIENTIFIC observation
Abstract

Objective: To report detailed age‐specific outcomes from the first round of an English pilot studying the implementation of high‐risk human papillomavirus (HR‐HPV) testing in primary cervical screening. Design: Observational study with screening in 2013–2016, followed by two early recalls and/or colposcopy until the end of 2019. Setting: Six NHS laboratory sites. Population: A total of 1 341 584 women undergoing screening with HR‐HPV testing or liquid‐based cytology (LBC). Methods: Early recall tests and colposcopies were recommended, depending on the nature of the screening‐detected abnormality. Main outcome measures: We reported standard screening process indicators, e.g. proportions with an abnormality, including high‐grade cervical intraepithelial neoplasia (CIN2+) or cancer, and the positive predictive value (PPV) of colposcopy for CIN2+, by screening test and age group. Results: Among unvaccinated women screened with HR‐HPV testing at age 24–29 years, 26.9% had a positive test and 10.4% were directly referred to colposcopy following cytology triage, with a PPV for CIN2+ of 47%. At 50–64 years of age, these proportions were much lower: 5.3%, 1.2% and 27%, respectively. The proportions of women testing positive for HR‐HPV without cytological abnormalities, whose early recall HR‐HPV tests returned negative results, were similar across the age spans: 54% at 24–29 years and 55% at 50–64 years. Two‐thirds of infections at any age were linked to non‐16/18 genotypes. Among women with CIN2, CIN3 or cervical cancer, however, the proportion of non‐16/18 infections increased with age. As expected, the detection of abnormalities was lower following screening with LBC. Conclusions: These data provide a reliable reference for future epidemiological studies, including those concerning the effectiveness of HPV vaccination. Data from the English pilot study provide a comprehensive overview of abnormalities detected through HPV screening. Data from the English pilot study provide a comprehensive overview of abnormalities detected through HPV screening. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

39. Patterns of anxiety and distress over 12 months following participation in HPV primary screening.

Author

Marlow, Laura A. V., McBride, Emily, Ridout, Deborah, Forster, Alice S., Kitchener, Henry, and Waller, Jo

Subjects
PAPILLOMAVIRUSES, RESEARCH, VERTEBRATES, RESEARCH methodology, MEDICAL screening, EARLY detection of cancer, PAP test, EVALUATION research, COMPARATIVE studies, VIRUS diseases, PAPILLOMAVIRUS diseases, QUESTIONNAIRES, RESEARCH funding, CERVIX uteri tumors, ANXIETY
Abstract

Objectives: Many countries are now using primary human papillomavirus (HPV) testing for cervical screening, testing for high-risk HPV and using cytology as triage. An HPV-positive result can have an adverse psychological impact, at least in the short term. In this paper, we explore the psychological impact of primary HPV screening over 12 months.Methods: Women were surveyed soon after receiving their results (n=1133) and 6 (n=762) and 12 months (n=537) later. Primary outcomes were anxiety (Short-Form State Anxiety Inventory-6) and distress (General Health Questionnaire-12). Secondary outcomes included concern, worry about cervical cancer and reassurance. Mixed-effects regression models were used to explore differences at each time point and change over time across four groups according to their baseline result: control (HPV negative/HPV cleared/normal cytology and not tested for HPV); HPV positive with normal cytology; HPV positive with abnormal cytology; and HPV persistent (ie, second consecutive HPV-positive result).Results: Women who were HPV positive with abnormal cytology had the highest anxiety scores at baseline (mean=42.2, SD: 15.0), but this had declined by 12 months (mean=37.0, SD: 11.7) and was closer to being within the 'normal' range (scores between 34 and 36 are considered 'normal'). This group also had the highest distress at baseline (mean=3.3, SD: 3.8, scores of 3+ indicate case-level distress), but the lowest distress at 12 months (mean=1.9, SD: 3.1). At 6 and 12 months, there were no between-group differences in anxiety or distress for any HPV-positive result group when compared with the control group. The control group were less concerned and more reassured about their result at 6 and 12 months than the HPV-positive with normal cytology group.Conclusions: Our findings suggest the initial adverse impact of an HPV-positive screening result on anxiety and distress diminishes over time. Specific concerns about the result may be longer lasting and efforts should be made to address them. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

40. Acceleration of cervical cancer diagnosis with human papillomavirus testing below age 30: Observational study.

Author

Rebolj, Matejka, Mathews, Christopher S., Pesola, Francesca, Castañon, Alejandra, and Kitchener, Henry

Subjects
CERVICAL cancer diagnosis, CERVICAL intraepithelial neoplasia, MEDICAL screening, EARLY detection of cancer, PAPILLOMAVIRUSES, CERVICAL cancer
Abstract

Several international cervical screening guidelines advise against using high‐risk human papillomavirus (HR‐HPV) testing in women younger than 30. The rationale for this in young women, lies in the potential for additional detection of both low‐grade and high‐grade cervical intraepithelial neoplasia (CIN) leading to unnecessary treatments without reducing the burden of cervical cancer. We studied 56 544 women screened at 24 to 29 with HR‐HPV testing and 116 858 screened with liquid‐based cytology (LBC) in the English HPV screening pilot. They were compared to 528 460 women screened at the age of 30 to 49. We studied the detection of cervical cancer and CIN2/3 across two consecutive screening rounds 3 years apart. At 24 to 29, a positive HR‐HPV test detected more cases of cervical cancer in the prevalence round than did a positive LBC test (1.36/1000 screened vs 0.82/1000, ORadj: 1.61, 95% CI: 1.18‐2.19). In women with a negative HR‐HPV test, cervical cancer was diagnosed before or at the incidence round in 0.07/1000. After a negative LBC test, cancer detection reached 0.47/1000 and 40% of these cases were diagnosed at FIGO stage IB+. HR‐HPV testing increased the detection of CIN2/3 diagnoses in two consecutive rounds combined by 30% (71.9/1000 vs 55.2/1000). The patterns of detection of cervical cancer and CIN2/3 were almost identical at older ages. These data support using HR‐HPV testing for screening of women younger than 30, which not only accelerates the diagnosis of cervical cancer but leads to a similar relative increase in CIN2/3 diagnosis to that found in women aged 30 to 49. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

42. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

Author

Paavonen, Jorma, Jenkins, David, Bosch, F Xavier, Naud, Paulo, Salmerón, Jorge, Wheeler, Cosette M, Chow, Song-Nan, Apter, Dan L, Kitchener, Henry C, Castellsague, Xavier, de Carvalho, Newton S, Skinner, S Rachel, Harper, Diane M, Hedrick, James A, Jaisamrarn, Unnop, Limson, Genara AM, Dionne, Marc, Quint, Wim, Spiessens, Bart, Peeters, Pascal, Struyf, Frank, Wieting, Susan L, Lehtinen, Matti O, and Dubin, Gary

Published
2007
Full Text
View/download PDF

49. The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome

Author

Crosbie, Emma J, Ryan, Neil AJ, Arends, Mark J, Bosse, Tjalling, Burn, John, Cornes, Joanna M, Crawford, Robin, Eccles, Diana, Frayling, Ian M, Ghaem-Maghami, Sadaf, Hampel, Heather, Kauff, Noah D, Kitchener, Henry C, Kitson, Sarah J, Manchanda, Ranjit, McMahon, Raymond FT, Monahan, Kevin J, Menon, Usha, Møller, Pål, Möslein, Gabriela, Rosenthal, Adam, Sasieni, Peter, Seif, Mourad W, Singh, Naveena, Skarrott, Pauline, Snowsill, Tristan M, Steele, Robert, Tischkowitz, Marc, Manchester International Consensus Group, Evans, D Gareth, Crosbie, Emma J [0000-0003-0284-8630], Evans, D Gareth [0000-0002-8482-5784], and Apollo - University of Cambridge Repository

Subjects
Ovarian Neoplasms, congenital, hereditary, and neonatal diseases and abnormalities, Consensus, Genital Neoplasms, Female, screening, nutritional and metabolic diseases, Colorectal Neoplasms, Hereditary Nonpolyposis, Endometrial Neoplasms, Europe, Lynch syndrome, endometrial cancer, North America, surveillance, Humans, Mass Screening, Female, guidance, Early Detection of Cancer
Abstract

PURPOSE: There are no internationally agreed upon clinical guidelines as to which women with gynecological cancer would benefit from Lynch syndrome screening or how best to manage the risk of gynecological cancer in women with Lynch syndrome. The Manchester International Consensus Group was convened in April 2017 to address this unmet need. The aim of the Group was to develop clear and comprehensive clinical guidance regarding the management of the gynecological sequelae of Lynch syndrome based on existing evidence and expert opinion from medical professionals and patients. METHODS: Stakeholders from Europe and North America worked together over a two-day workshop to achieve consensus on best practice. RESULTS: Guidance was developed in four key areas: (1) whether women with gynecological cancer should be screened for Lynch syndrome and (2) how this should be done, (3) whether there was a role for gynecological surveillance in women at risk of Lynch syndrome, and (4) what preventive measures should be recommended for women with Lynch syndrome to reduce their risk of gynecological cancer. CONCLUSION: This document provides comprehensive clinical guidance that can be referenced by both patients and clinicians so that women with Lynch syndrome can expect and receive appropriate standards of care.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results